The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
Curated pathway from expert analysis
flowchart TD
A["Sex-Specific Microglial States<br/>X-Linked Gene Dose Effect"]
B["Perturbation-First Validation<br/>Microglial State Modulation Testing"]
C["Female vs Male Microglial Response<br/>Amyloid and Tau Pathology Models"]
D["Cognitive Decline Trajectory<br/>Sex-Dimorphic Outcome Measurement"]
E["Mechanism Confirmation<br/>X-Chromosome Escape Gene Contribution"]
F["AD Personalized Medicine<br/>Sex-Specific Microglial Targeting"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.